Singapore, June 26 -- US based Synchron Inc., a neurovascular bioelectronic medicine company, has announced that the University of Melbourne has been awarded an AUD$1.5M Medical Research Future Fund grant from the National Health and Medical Research Council (NHMRC) of the Australian Government to expand the current clinical study of Synchron's Stentrode(R).

The study is the first clinical trial to evaluate the safety and efficacy of the Stentrode, the first interventional neuromodulation platform. This technology is designed to translate brain activity from the inside of a blood vessel, and is being explored for its potential to enable hands-free control of devices for people with upper limb paralysis.

"Having this support from the Aus...